Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
Aytu BioPharma Inc (NASDAQ: AYTU) closed the day trading at $1.86 down -9.71% from the previous closing price of $2.06. In other words, the price has decreased by -$9.71 from its previous closing price. On the day, 0.54 million shares were traded. AYTU stock price reached its highest trading level at $2.0881 during the session, while it also had its lowest trading level at $1.82.
Ratios:
For a better understanding of AYTU, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.07 and its Current Ratio is at 1.26. In the meantime, Its Debt-to-Equity ratio is 1.21 whereas as Long-Term Debt/Eq ratio is at 0.63.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Lake Street on July 01, 2025, initiated with a Buy rating and assigned the stock a target price of $8.
On June 30, 2025, Ascendiant Capital Markets started tracking the stock assigning a Buy rating and target price of $12.
On March 30, 2021, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $11.Cantor Fitzgerald initiated its Overweight rating on March 30, 2021, with a $11 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 09 ’25 when Disbrow Jarrett bought 16,666 shares for $1.50 per share. The transaction valued at 24,999 led to the insider holds 29,462 shares of the business.
Disbrow Joshua R. bought 66,666 shares of AYTU for $99,999 on Jun 09 ’25. The Chief Executive Officer now owns 153,257 shares after completing the transaction at $1.50 per share. On Feb 28 ’25, another insider, Disbrow Joshua R., who serves as the Chief Executive Officer of the company, bought 15,000 shares for $1.30 each. As a result, the insider paid 19,500 and bolstered with 86,591 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AYTU now has a Market Capitalization of 18436158 and an Enterprise Value of 9299158. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.28 while its Price-to-Book (P/B) ratio in mrq is 0.88. Its current Enterprise Value per Revenue stands at 0.14 whereas that against EBITDA is 1.175.
Stock Price History:
The Beta on a monthly basis for AYTU is 0.30, which has changed by -0.21186441 over the last 52 weeks, in comparison to a change of 0.15101504 over the same period for the S&P500. Over the past 52 weeks, AYTU has reached a high of $2.85, while it has fallen to a 52-week low of $0.95. The 50-Day Moving Average of the stock is -20.84%, while the 200-Day Moving Average is calculated to be 5.72%.
Shares Statistics:
Over the past 3-months, AYTU traded about 180.38K shares per day on average, while over the past 10 days, AYTU traded about 440370 shares per day. Insiders hold about 12.52% of the company’s shares, while institutions hold 55.37% stake in the company. Shares short for AYTU as of 1756425600 were 464467 with a Short Ratio of 2.56, compared to 1753920000 on 585164. Therefore, it implies a Short% of Shares Outstanding of 464467 and a Short% of Float of 6.550000000000001.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 2 analysts currently analyzing and rating the stock of Aytu BioPharma Inc (AYTU).The consensus estimate for the next quarter is -$0.61, with high estimates of -$0.48 and low estimates of -$0.74.
Analysts are recommending an EPS of between -$0.91 and -$1.63 for the fiscal current year, implying an average EPS of -$1.27. EPS for the following year is $0.09, with 2.0 analysts recommending between $0.3 and -$0.12.
Revenue Estimates
3 analysts predict $12.6M in revenue for the current quarter. It ranges from a high estimate of $13M to a low estimate of $12.18M. As of the current estimate, Aytu BioPharma Inc’s year-ago sales were $16.57MFor the next quarter, 3 analysts are estimating revenue of $12.74M. There is a high estimate of $13.5M for the next quarter, whereas the lowest estimate is $11.71M.
A total of 3 analysts have provided revenue estimates for AYTU’s current fiscal year. The highest revenue estimate was $60.7M, while the lowest revenue estimate was $52.33M, resulting in an average revenue estimate of $55.23M. In the same quarter a year ago, actual revenue was $66.38MBased on 3 analysts’ estimates, the company’s revenue will be $82.15M in the next fiscal year. The high estimate is $102.2M and the low estimate is $70.08M.
